Drug Formulary Review articles from March 2007

Drug Formulary Review archives from March 2007

Early statin withdrawal can endanger patients with acute coronary syndrome.
March 1, 2007... Early statin withdrawal can endanger patients with acute coronary syndrome Pharmacists should be aware of 'rebound' effect The benefits of statins on acute coronary outcomes are rapidly lost and outcomes worsened if statins are...

Hospitalized patients also at risk for VTE.
March 1, 2007... Hospitalized patients also at risk for VTE May warrant consideration for prophylaxsis Research conducted by Policy Analysis, Inc., Brookline, MA, and reported in the American Journal of Health-System Pharmacy, found that the risk of...

Setting record straight on VA pharmacy system.
March 1, 2007... Setting record straight on VA pharmacy system Both praise, blame stem from misconceptions Department of Veterans Affairs chief pharmacy officer Michael Valentino, R.Ph., says much of the praise and criticism his organization's pharmacy...

Pharmacists help with ED smoking cessation efforts.
March 1, 2007... Pharmacists help with ED smoking cessation efforts Many smokers seek primary care in EDs Smoking cessation is a timely topic and efforts to curb tobacco use are widely discussed in the medical literature. MLC Solutions principals...

FDA moving to strengthen drug safety program.
March 1, 2007... FDA moving to strengthen drug safety program Canadian pharmacists increase safety as well The U.S. Food and Drug Administration have asked Congress to make changes as part of reauthorization of the Prescription Drug User Fee Act...

Drug Criteria & Outcomes: Bad to the (jaw) bone:.
March 1, 2007... Drug Criteria & Outcomes Bad to the (jaw) bone: Avoiding ADRs in cancer patients receiving IV bisphosphonates By Brandy Puet, PharmD Candidate, Auburn (AL) University Physician, dentist collaboration necessary The recent...

Drug Criteria & Outcomes: New FDA Approvals.
March 1, 2007... Drug Criteria & Outcomes FDA recently approved these drugs: *Connetics' Olux-E (clobetasol propionate) foam, 0.05%, was approved for treating inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. FDA noted...

CE objectives/questions.
March 1, 2007... CE objectives/questions This CE program will improve participants' ability to: *Compare the clinical efficacy and safety of one therapeutic agent over another used in the same setting. *Assess clinical trial data and explain how...